ViaDerma, Inc. announced their plans to launch a new hair regrowth product using Minoxidil (topical route). The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product. ViaDerma's unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market.

This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments. Previous testing conducted by ViaDerma has yielded exceptional results at regrowing hair. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength and Lipogaine.

FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later in the year 2023.